Neural stem cells, which differentiate into neurons and glia, are present in the ventricular zone of the embryonal brain. The precise mechanism by which neural stem cells are maintained during embryogenesis remains to be determined. Here, we found that transient misexpression of the basic helix-loop-helix genes Hes1 and Hes5 keeps embryonal telencephalic cells undifferentiated although they have been shown to induce gliogenesis in the retina. These telencephalic cells later differentiate into neurons and astroglia when Hes expression is down-regulated, suggesting that Hes1-and Hes5-expressing cells are maintained as neural stem cells during embryogenesis. Conversely, in the absence of Hes1 and Hes5, neural stem cells are not properly maintained, generating fewer and smaller neurospheres than the wild type. These results indicate that Hes1 and Hes5 play an important role in the maintenance of neural stem cells but not in gliogenesis in the embryonal telencephalon.
1 genes Hes1 and Hes5 are expressed in the ventricular zone of the developing nervous system, which contains neural stem cells (5) (6) (7) (8) . Misexpression of Hes1 and Hes5 inhibits neuronal differentiation, whereas mice that are mutant for Hes1 and Hes5 display premature neurogenesis (7, 9 -17) , indicating that these Hes genes are negative regulators of neuronal differentiation. However, it is not known whether Hes-expressing cells remain as neural stem cells or become glia in the embryonal brain. In the retina, both Hes1 and Hes5 are expressed by differentiating Mü ller glia, and misexpression of Hes1/5 promotes the generation of Mü ller glia at the expense of neurons, whereas the inactivation of Hes1/5 results in defects of Mü ller glial development (18, 19) . Thus, these Hes genes are capable of not only inhibiting neurogenesis but also promoting retinal gliogenesis. Interestingly, the membrane protein Notch, which controls Hes1/5 expression, has also been shown to inhibit neurogenesis while inducing gliogenesis (11, 19 -24) , suggesting that Hes1 and Hes5 regulate neurogenesis and gliogenesis as Notch effectors. Strikingly, in the peripheral nervous system (PNS), even transient activation of Notch signaling is sufficient to irreversibly inhibit neurogenesis and instruct gliogenesis (22) . However, these findings contrast the previous observation that Notch signaling is involved in the maintenance of the undifferentiated state and only allows, rather than instructs, gliogenesis (25, 26) . It is likely that different cells may respond in different ways to the same signal, and it remains to be determined whether in the brain, the Notch-Hes pathway instructs cells to become glia, as in the retina and PNS, or to remain undifferentiated.
Here, to determine the functions of Hes1 and Hes5 in the developing brain, we performed gain-of-function and loss-offunction studies. We found that transient misexpression of Hes1 or Hes5 in the embryonal brain inhibits both neurogenesis and gliogenesis, in contrast with the retina and PNS, and keeps cells undifferentiated. However, these undifferentiated cells later become neurons and glia when Hes expression is down-regulated, suggesting that Hes1 ϩ and Hes5 ϩ cells remain as neural stem cells. Conversely, in the absence of Hes1 and Hes5, neural stem cells are not properly maintained, generating fewer and smaller neurospheres. These results indicate that Hes1 and Hes5 play an important role in the maintenance of neural stem cells but not in gliogenesis in the embryonal brain.
EXPERIMENTAL PROCEDURES

Introduction of Expression Vectors into Telencephalic Cells of Mouse
Embryos by Electroporation-Rat Hes1 and Hes5 cDNAs were inserted into the EcoRI site of pCLIG (18) , which directs gene expression from the upstream long terminal repeat promoter with cytomegalovirus enhancer. This vector also directs enhanced green fluorescent protein (EGFP) expression through the internal ribosomal entry site.
For the introduction of DNA, pregnant mice were deeply anesthetized, and a ventral midline incision was made to perform in utero manipulation. The expression vector (5 g) in solution containing 0.05% trypan blue as a tracer was injected through the uterine wall with a glass micropipette into the telencephalic vesicle of each embryo in utero. 1 g of pCL-EGFP was also co-injected with the expression vectors in many cases because EGFP ϩ cells can be more easily identified (the same results were obtained). The volume of the injected DNA solution was kept minimal (mostly about 1 l). After injection, electroporation was carried out as described previously (27) . Electrodes CUY 650 -5 (: 5 mm) or CUY 650P10 (: 10 mm) were placed outside of the uterus on both sides of the head of the embryo in utero. A square electroporator CUY21 EDIT (TR Tech, Tokyo, Japan) was used to deliver five 50-ms pulses of 50 V with 950-ms intervals. Then the abdominal wall of the pregnant mouse was sutured. Embryos or neonates were harvested 2-7 days after electroporation. The brains were excised, fixed in 4% paraformaldehyde in PBS for 30 min at 4°C, cryoprotected in 25% sucrose in PBS overnight, and embedded in OCT compound. 16 mthick cryosections were cut and examined immunohistochemically.
Neurosphere Assay-The primary sphere formation assay was performed essentially as described previously (17, 28) . The uterus of the pregnant mouse was dissected at E11.5, and the heads of the embryos were excised. With fine forceps, the epidermis, mesenchyme, and meninges were removed. The neuroepithelium of the dorsal telencephalon was transferred into the neurosphere culture medium (Dulbecco's modified Eagle's medium/F-12 (1:1) (Life Technologies, Inc.) supplemented with 100 g/ml transferrin (Sigma), 25 g/ml insulin (Sigma), 20 nM progesterone (Sigma), 30 nM sodium selenite (Sigma), 60 M putrescine (Sigma), 20 ng/ml epidermal growth factor (EGF; Life Technologies, Inc.), and 20 ng/ml basic fibroblast growth factor (bFGF; Life Technologies, Inc.)), washed in PBS once, and digested with 0.25% trypsin-EDTA (Life Technologies, Inc.) and DNaseI (50 g/ml) for 15 min at 37°C. 0.25% trypsin inhibitor and PBS were added, and the cells were spun down, resuspended in the neurosphere culture medium, and dissociated completely by pipetting. 50 l of the cell suspension (at a density of 1 ϫ 10 6 cells/ml) were plated in each well of 96-well ultralow attachment plates (Corning). The numbers of primary spheres were counted, and the sphere sizes were compared at days 10 and 14.
For the secondary sphere formation assay, primary spheres were collected at day 7, spun down at 600 rpm for 1 min, and digested with 0.25% trypsin-EDTA and DNaseI (50 g/ml) for 15 min at 37°C. 0.25% trypsin inhibitor and PBS were added, and the cells were spun down, resuspended in the neurosphere culture medium, and dissociated completely by pipetting. 40 l of the cell suspension (at a density of 5 ϫ 10 4 cells/ml) were plated in each well of 96-well ultralow attachment plates. The numbers of secondary spheres and the sphere sizes were examined at day 7.
Sphere Differentiation Assay-Secondary spheres were collected and plated onto polyethylenimine-(Sigma) and fibronectin-(Life Technologies, Inc.) coated Lab-Tek chamber slides (Nalge Nunc) in the differentiation medium (Dulbecco's modified Eagle's medium/F-12 (1:1) supplemented with 2% fetal bovine serum, 25 g/ml transferrin, 15 g/ml insulin, 20 nM progesterone, 30 nM sodium selenite, 3.3 ng/ml EGF, 1.7 ng/ml bFGF, 10 ng/ml nerve growth factor (Life Technologies, Inc.), and 10 ng/ml cholera toxin (Sigma)). After 7 days of culture, cells were fixed in 4% paraformaldehyde in PBS for 10 min at room temperature and examined immunocytochemically. Neuronal and glial differentiation was defined by triple-labeled immunocytochemistry using anti-MAP2 (neuron), anti-GFAP (astrocyte), and anti-O4 (oligodendrocyte) antibodies described below.
Immunohistochemistry and Immunocytochemistry-Fixed cryosections were washed three times with PBS and preincubated in PBS containing 5% normal goat serum and 0.1% Triton X-100 for 30 min and then incubated in 1% normal goat serum and 0.1% Triton X-100 with the following antibodies. Primary antibodies used are as follows: rabbit anti-GFP (diluted 1:500; Medical and Biological Laboratories), rabbit anti-GFP (1:1000; Molecular Probes), mouse anti-MAP2 (1:500; Sigma), mouse anti-␤III-tubulin (1:2000; BAbCO), mouse anti-RC2 (IgM, 1:2; Developmental Studies Hybridoma Bank, Iowa City, IA), mouse antinestin (1:500; PharMingen), mouse anti-GFAP (1:400; Sigma), rabbit anti-GFAP (1:10; Dako), mouse anti-S100␤ (1:250; Sigma), mouse anti-O4 (IgM, 1:5; Chemicon), mouse anti-GalC (IgG3, 1:20; Chemicon), mouse anti-Ki67 (1:100; PharMingen), mouse anti-Myc (1:500; Invitrogen), and rabbit anti-Myc (1:500; Medical and Biological Laboratories). To detect these antibodies, biotinylated goat anti-mouse IgM (7.5 g/ml; Vector), fluorescein isothiocyanate-conjugated goat anti-rabbit IgG (1: 200; Vector), fluorescein isothiocyanate-conjugated goat anti-mouse IgM (1:500; ICN/CAPPEL), 7-amino-4-methylcoumarin-3-acetic acidconjugated goat anti-rabbit IgG (1:100; Jackson), Fluorolink Cy3-labeled goat anti-mouse IgG (1:400; Amersham Pharmacia Biotech), Cy3-conjugated goat anti-mouse IgM (1:400; Jackson), and Fluorolink Cy3-labeled streptavidin (1:1000; Amersham Pharmacia Biotech) were used. Fluorescently labeled preparations were imaged using a Carl Zeiss LSM510 confocal microscope or a Carl Zeiss Axiophoto2 microscope equipped with an AxioCam color CCD camera. The images were processed by Photoshop 4.0 software (Adobe).
Hes1 Ϫ/Ϫ and Hes5 Ϫ/Ϫ mutant mice, the 0.9-kb BamHI-PvuII fragment was used as a probe as described previously (15) . This probe detected a 12-kb wild-type band and a 2.3-kb mutant band. For genotyping of Hes5 Ϫ/Ϫ mutant mice, a 0.9-kb SmaI-BamHI fragment was used as a probe (16) . This probe detected a 7-kb wild-type band and a 4-kb mutant band. Hes1 Ϫ/Ϫ -Hes5 Ϫ/Ϫ double-null embryos were obtained by crossing Hes1
RESULTS
Misexpression of Hes1 and Hes5 Maintains Undifferentiated Cells in the Ventricular Zone of the Embryonal Telencephalon-
During neural development, Hes1 and Hes5 are specifically expressed in the ventricular zone (5, 6, 8) . To examine their functions in the developing brain, we injected the expression vectors into the telencephalic vesicle of mouse embryos and introduced the vector DNA into telencephalic cells by electroporation (Fig. 1A) . By this method, the exogenous genes can be transiently misexpressed in embryonal telencephalic cells.
EGFP alone or together with Hes1 or Hes5 was misexpressed in telencephalic cells at E13.5, and after 2 days (E15.5), the fates of the transfected cells (EGFP ϩ ) were determined. When EGFP alone was misexpressed, the majority of the EGFP ϩ cells migrated out of the ventricular zone into the outer layers during the E13.5-E15.5 period (Fig. 1B) . Some of them reached the cortical plate and expressed the neuronal markers MAP2 (Fig. 1 , B-D) and ␤III-tubulin (data not shown), indicating that many of the ventricular cells underwent neurogenesis during the E13.5-E15.5 period. This result is consistent with the previous observation that neurogenesis proceeds during the E13.5-E15.5 period (29) . In contrast, when Hes1 or Hes5 was misexpressed together with EGFP, almost all transfected cells (EGFP ϩ ) remained in the ventricular zone ( Fig. 1 , F and J). These transfected cells were negative for MAP2 (Fig. 1 , G, H, K, and L) and ␤III-tubulin (data not shown), indicating that Hes1 and Hes5 inhibit neurogenesis. Because these EGFP ϩ cells were also negative for the astrocytic markers GFAP and S100␤ and the oligodendrocytic marker GalC (data not shown), Hes1 and Hes5 did not promote gliogenesis during the E13.5-E15.5 period. To verify the expression of Hes1 and Hes5, three repeats of the Myc epitope were fused in frame to Hes1 and Hes5 at the amino terminus, and the Myc expression was examined. We found that the majority of the cells in the EGFP ϩ region displayed a high level of nuclear staining of Myc (Fig. 1, I and M). We also observed inhibition of neurogenesis when Hes1 and Hes5 without Myc tags were misexpressed (data not shown), thus excluding the possibility that the Myc epitope affected the Hes functions.
To further determine whether the Hes1-EGFP ϩ and Hes5-EGFP ϩ ventricular cells are in a mitotic phase, we performed immunohistochemistry for Ki67, a nuclear antigen expressed by proliferating cells. Many of the Hes1-EGFP ϩ (Fig. 2 A and D) ). This morphology is typical of radial glial cells, which have cell bodies in the ventricular zone and extend long processes from the ventricular zone to the pial surface (30). To determine whether these transfected cells are radial glia, we examined radial glial markers RC2 and nestin. The cell bodies and processes of almost all Hes1-EGFP ϩ and Hes5-EGFP ϩ cells were positive for RC2 (Fig. 3, A-C and G-I) and nestin (data not shown). In addition, the end-feet of Hes1-EGFP ϩ and Hes5-EGFP ϩ processes were positive for RC2 (Fig.  3, D-F and J-L) . These results indicate that misexpression of Hes1 and Hes5 promotes the generation of radial glia during the E13.5-E15.5 period. It was believed previously that radial glial cells are the specialized glia that guide the migration of neurons (30). However, recent studies revealed that radial glial cells are identical to neural stem cells (31, 32) . Thus, these results strongly suggest that Hes1 and Hes5 may play an important role in the maintenance of neural stem cells but do not induce gliogenesis in the embryonal brain, unlike in the retina and PNS. This effect is very similar to that of the active form of Notch1, which also predominantly induces radial glia when misexpressed at an earlier stage of development (23), consistent with the notion that Notch1 and Hes1/5 function in the same pathway (11, 20, 33) . 2 Hes expression disappeared in many of the transfected cells during embryogenesis (Fig. 4, D, H , L, and P), whereas EGFP expression remained postnatally in many cells (Fig. 4, A, E, I , and M), which enabled us to determine the postnatal fates of the transfected cells (EGFP ϩ ). When EGFP alone was misexpressed at E13.5, the majority of the EGFP ϩ cells differentiated into neurons present in the deep layers of the cortex at postnatal day 1 (P1) (Fig. 4Q) . When Hes1 or Hes5 together with EGFP was misexpressed at E13.5, many of the transfected cells now migrated out of the ventricular zone and differentiated into neurons, which were located in the superficial layers of the cortex at P1 (Fig. 4, A-C and  I-K) . Because these EGFP ϩ cells in the cortex lost Hes1 and Hes5 expression (Fig. 4, D and L) , it is likely that the cells that lost expression of Hes1 and Hes5 underwent neuronal differentiation. Because these neurons were present in more superficial layers than the neurons of EGFP misexpression alone (Fig. 4 , A and I versus Q), the former neurons were born later than the latter. When EGFP alone was misexpressed at E15.5, neurons were generated in the superficial layers (Fig. 4R) , suggesting that Hes1 and Hes5 delayed neuronal differentiation for at least 2 days. We also found that many of the EGFP ϩ cells remained near the ventricle and that those cells differentiated into GFAP ϩ astrocytes at P1 (Fig. 4 
Cells That Are Inhibited from Differentiation by Hes1 or Hes5 Later Differentiate into Neurons and Glia-If
the Hes1-EGFP ϩ and Hes5-EGFP ϩ ventricular cells are neural stem cells, they should differentiate into neurons and glia when Hes1 and Hes5 expression disappears. To determine the later fates of the ventricular cells that are inhibited from differentiation by Hes1 and Hes5, the telencephalons transfected at E13.5 were examined postnatally. Because Hes1 and Hes5 proteins are unstable compared with EGFP,
, E-G and M-O).
These results demonstrated that the cells that are inhibited from differentiation by Hes1 or Hes5 later differentiate into neurons and glia, consistent with the above notion that Hes1 and Hes5 maintain neural stem cells in the embryonal brain. Immunostaining indicated that some of the cells near the ventricle still expressed Hes1 and Hes5 (Fig. 4, H and P E11.5 and cultured in the presence of EGF and bFGF. After 7 days, many neurospheres were formed in cultures prepared from wild-type, Hes1 Ϫ/Ϫ , and Hes5 Ϫ/Ϫ embryos (Fig. 5, A-C) . After 14 days, these neurospheres became larger, although Hes1 Ϫ/Ϫ spheres were smaller than the wild-type and Hes5 Ϫ/Ϫ spheres ( Fig. 6, E-G) . In contrast, Hes1 Ϫ/Ϫ -Hes5 Ϫ/Ϫ neurospheres were significantly smaller in size and did not seem to expand during the culture period (Fig. 5, D and H) .
To quantify the number and size of neurospheres, an equal number (5 ϫ 10 4 ) of cells prepared from the E11.5 telencephalon of wild-type, Hes1 Ϫ/Ϫ , Hes5 Ϫ/Ϫ , and Hes1 Ϫ/Ϫ -Hes5 Ϫ/Ϫ embryos were plated and cultured in low attachment dishes. Because it was sometimes difficult to distinguish between small neurospheres and dying cell clusters, only spheres larger than 50 m in diameter were counted. At day 10, the majority of neurospheres was still less than 100 m in diameter in all cultures (Fig. 6A) (Fig. 6A) . In contrast, larger spheres were not increased in Hes1 Ϫ/Ϫ -Hes5 Ϫ/Ϫ cultures at day 14 (average size: 91.9 m), suggesting that the expansion of Hes1 Ϫ/Ϫ -Hes5 Ϫ/Ϫ spheres stopped (Fig. 6A) . Furthermore, whereas there were on average of 11.6 neurospheres that were larger than 300 m in diameter in the wild-type and Hes5 Ϫ/Ϫ cultures and 6.3 neurospheres in Hes1 Ϫ/Ϫ cultures, there were no such neurospheres in Hes1 Ϫ/Ϫ -Hes5 Ϫ/Ϫ cultures at day 14 (Fig. 6A) . These results indicate that Hes1 and Hes5 are required for the normal expansion of neurospheres.
To examine the self-renewal activity of sphere-forming cells, the above neurospheres were dissociated, and an equal number (2 ϫ 10
3 ) of cells were replated to form secondary spheres. At day 7, there were ϳ90 -100 spheres larger than 50 m in the wild-type, Hes1 Ϫ/Ϫ , and Hes5 Ϫ/Ϫ cultures, whereas there were only 20 in Hes1 Ϫ/Ϫ -Hes5 Ϫ/Ϫ cultures (Fig. 6B) . These results indicate that the number of cells with the self-renewal activity was significantly reduced in the absence of Hes1 and Hes5. In addition, from 2 ϫ 10 3 replated cells, 5-8 spheres became larger than 300 m at day 7 in the wild-type, Hes1 Ϫ/Ϫ , and Hes5 Ϫ/Ϫ cultures, whereas virtually no such spheres were formed in Hes1 Ϫ/Ϫ -Hes5 Ϫ/Ϫ cultures (Fig. 6B) . Thus, the growth rate of sphere-forming cells was also significantly reduced in the absence of Hes1 and Hes5. Hes1 Ϫ/Ϫ -Hes5 Ϫ/Ϫ Double-mutant Sphere-forming Cells Are Multipotential-To examine the differentiation activity of sphere-forming cells, secondary spheres were plated down in polyethylenimine-and fibronectin-coated dishes and cultured in a differentiation medium. Almost all spheres (Ͼ90%) from the wild-type and Hes1 Ϫ/Ϫ -Hes5 Ϫ/Ϫ cultures generated mixtures of neurons, astrocytes, and oligodendrocytes (Fig. 7,  A-D) . Because it is likely that each sphere arose from a single cell, such sphere-forming cells may represent multipotential neural stem cells. These results indicate that, although the number and growth rate of neural stem cells were severely reduced in the absence of Hes1 and Hes5, their multipotentiality of differentiation was not lost. In addition, cells of secondary spheres from both the wild-type and Hes1 Ϫ/Ϫ -Hes5 Ϫ/Ϫ cultures very efficiently differentiated into astrocytes and oligodendrocytes (Fig. 7, E-H) . Thus, Hes1 and Hes5 mutation did not affect the generation of astrocytes and oligodendrocytes, con- Ϫ/Ϫ -Hes5 Ϫ/Ϫ neural stem cells form spheres larger than 300 m in diameter, whereas wild-type stem cells efficiently form such large spheres. It is likely that most of Hes1 Ϫ/Ϫ -Hes5 Ϫ/Ϫ neural stem cells stop cell division and differentiate into neurons and glia. These results are consistent with the previous observation that mutations for Hes1 and/or Hes5 lead to premature neuronal differentiation (7, 11, 15, 17) .
It remains to be determined how Hes1 and Hes5 maintain the undifferentiated state of neural stem cells. It has been shown that Hes1 is able to down-regulate the expression of p21, a cyclin-dependent kinase inhibitor, which is required for exit from the cell cycle (35) . Hes1 represses p21 expression not only by directly binding to its promoter but also by inhibiting Mash1-dependent activation (35) . It is likely that this repression of p21 expression leads to cell proliferation and the maintenance of the undifferentiated state.
Despite the severe abnormalities, Hes1 Ϫ/Ϫ -Hes5 Ϫ/Ϫ neural stem cells still proliferate and form small neurospheres. This observation indicates that there may be another Hes1/5-related gene involved in the maintenance of neural stem cells. It has been shown that a splicing variant of Hes3, named Hes3b, is expressed at a high level in the midbrain-hindbrain and at lower levels in other regions (13, 36) . Hes3b encodes a complete bHLH domain and inhibits neuronal and glial differentiation similarly to Hes1 but in contrast to the other splicing variant Hes3a that has an incomplete basic region and does not inhibit neuronal differentiation (6, 13) . Therefore, it is likely that Hes3b may also contribute to the maintenance of neural stem cells in the embryonal brain.
We previously found that the number of sphere-forming cells was reduced in the absence of Hes1 (17) . However, in the present study, although the growth rate of Hes1 Ϫ/Ϫ neurospheres was reduced, their number was not significantly affected, suggesting that Hes1 Ϫ/Ϫ phenotypes became weaker. This change may be attributable to different genetic backgrounds of Hes1-mutant mice; the previous genetic background is the mixture of ICR and 129 strains, whereas the current one is substantially ICR.
Hes1 and Hes5 Do Not Induce Astrocytes or Oligodendrocytes in the Embryonal
Telencephalon-In the embryonal telencephalon, Hes1 and Hes5 do not induce the development of astrocytes or oligodendrocytes but maintain undifferentiated cells in the ventricular zone. Consistent with this misexpression study, the efficiency of gliogenesis is not affected by Hes1 and Hes5 mutation; Hes1 Ϫ/Ϫ -Hes5 Ϫ/Ϫ cells differentiate very efficiently into astrocytes and oligodendrocytes. Therefore, it is unlikely that the Notch-Hes1/5 pathway determines the fate of astrocytes and oligodendrocytes in the developing telencephalon. In contrast, in the PNS, neural crest stem cells differentiate into neurons in the presence of BMP2 but, upon Notch activation, they adopt the glial fate, indicating that Notch directs the fate switch from neurons to glia (22) . Strikingly, even transient activation of Notch signaling is sufficient for gliogenesis from neural crest stem cells. In a sharp contrast to neural crest stem cells, many of the Hes1 ϩ and Hes5 ϩ ventricular cells of the telencephalon later differentiate into neurons, indicating that the Notch-Hes pathway does not irreversibly induce gliogenesis in the brain. Alternatively, Notch signaling may play an important role in the generation of late-born neurons in the cortex by transiently preventing neurogenesis. Thus, different cells respond in different ways to the Notch-Hes pathway, but the molecular basis for these diverse responses remains to be determined.
bHLH Genes in Neuron/Glia Fate Determination-In the retina, Notch signaling has been found to promote Mü ller glial development at the expense of the neuronal fate (18, 19) . Interestingly, induction of Mü ller glial development is also observed in double-mutant mice for the neuronal bHLH genes Mash1 and Math3 (37, 38) . In these mutant retina, the cells that normally differentiate into bipolar neurons adopt the Mü ller glial fate (37, 38) . In other regions of the nervous system of Mash1-Math3 double-mutant mice, the cells that normally differentiate into neurons adopt the astrocytic fate, resulting in a loss of neurons and premature generation of astyrocytes (37) . Similarly, the double mutation of Mash1 and Neurogenin2, another neuronal bHLH gene, leads to a decrease of neurons and premature generation of astyrocytes (39 Ϫ/Ϫ -Hes5 Ϫ/Ϫ (C, D, G, and H) were plated in polyethylenimine-and fibronectin-coated dishes and cultured in the differentiation medium. The cell types were examined by immunocytochemistry with anti-MAP2 (neuron), anti-GFAP (astrocyte), anti-O4 (oligodendrocyte), and anti-GalC antibodies (oligodendrocyte). Both wild-type and Hes1 Ϫ/Ϫ -Hes5 Ϫ/Ϫ secondary spheres differentiated into mixtures of neurons, astrocytes, and oligodendrocytes, indicating that these sphere-forming cells are multipotential. Scale bar, 100 m.
bHLH genes such as Mash1, Math3, and Neurogenin not only determine the neuronal fate but also actively inhibit gliogenesis. Consistent with this notion, overexpression of Neurogenin1 actively inhibits astrocyte differentiation (40) . These results raised the possibility that down-regulation of neuronal bHLH genes is one of the mechanisms that initiates gliogenesis. Because Hes1 and Hes5 functionally antagonize neuronal bHLH factors (6, 9, 41) , it is likely that misexpression of Hes1 and Hes5 may inactivate Mash1 and Math3, thereby inducing gliogenesis in the retina. However, misexpression of Hes1 and Hes5 did not induce astrocyte development in the embryonal brain. We found that some of the Hes1 ϩ and Hes5 ϩ cells later differentiate into astrocytes at P1. However, this cell type is unlikely to be directly induced by Hes1 and Hes5 but most likely to be a secondary fate from neural stem cells because these astrocytes appear only around the perinatal period. Thus, the Notch-Hes pathway may only secondarily promote astrocyte development in the brain by maintaining neural stem cells until astrocytic differentiation occurs. Recent studies suggest that misexpression of Id1, a helixloop-helix factor that dominant-negatively regulates neuronal bHLH factors, generates astrocytes (42) . However, these astrocytes also appear only postnatally, and therefore, the astrocytic fate choice by Id1 could be indirect.
Currently, we do not have a clear answer as to why activation of the Notch-Hes pathway induces gliogenesis in the retina but not in the brain, although inactivation of Mash1, Math3, and Neurogenin2 induces gliogenesis in both the retina and brain. It is possible that the Notch-Hes1/5 pathway may suppress astrocytic genes in addition to Mash1, Math3, and Neurogenin in the brain as observed for oligodendrocyte development in the optic nerve, which is inhibited by the Notch-Hes5 pathway (43) . It has been shown that Notch signaling is modulated by many factors, such as Numb and Mastermind (21) . Thus, the Notch-Hes1/5 pathway could be modulated by such factors so that neurogenesis but not gliogenesis is blocked. Further characterization of Notch modulators is necessary to understand the diverse functions of Notch signaling.
